- $1.71bn
- $1.50bn
- $69.65m
Brief: Cate Clinical Trial Launched To Demonstrate The Clinical Utility Of Ctdna-Guided Treatment In Breast Cancer Using The Ultrasensitive Next Personal Test
Brief: Personalis Announces New Data From Neoadjuvant Lung Cancer Trial
Personalis Inc reports results for the quarter ended June 30 - Earnings Summary
Healthcare firm Personalis' Q2 revenue misses estimates
Personalis Inc expected to post a loss of 24 cents a share - Earnings Preview
Brief: Personalis Announces Inducement Grants
Personalis Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Personalis Q1 Net Income USD -15.75 Million Vs. IBES Estimate USD -20.4 Million
Personalis Inc expected to post a loss of 25 cents a share - Earnings Preview
Brief: Personalis Files Prospectus Covers Offer, Resale By Selling Stockholders Of Up To 14 Million Shares Of Common Stock
Personalis Inc reports results for the quarter ended December 31 - Earnings Summary
Brief: Personalis Q4 Net Income USD -16.425 Million Vs. IBES Estimate USD -19 Million
Personalis Inc expected to post a loss of 28 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Ares Management, Evercore, Tompkins Financial
Brief: Personalis Advances Business Strategy With Investment From Merck And Extends Collaboration With Moderna
Personalis Inc reports results for the quarter ended in September 30 - Earnings Summary
Brief: Personalis Q3 Net Income USD -39.089 Million Vs. IBES Estimate USD -18.9 Million
Personalis Inc expected to post a loss of 35 cents a share - Earnings Preview
Brief: Personalis - Received New Task Order Under Contract With U.S. Department Of Veterans Affairs (Va) For Va's Million Veteran Program (Va Mvp)